Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022

REHOVOT, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
November 22, 2021 07:05 ET | Source: Kamada Ltd.

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products

2021 Global Revenue of the Portfolio Acquired from Saol Therapeutics is Estimated Between $40 Million to $45 Million, with Approximately 75% and 20% of Sales Generated from U.S. and Canada,...
November 22, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products

Third Quarter 2021 Revenues were $23.0 Million and Total Revenues for the First Nine Months of 2021 were $72.2 MillionKamada has Acquired a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune...
November 08, 2021 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Third Quarter Financial Results and Host Conference Call on November 22, 2021

REHOVOT, Israel, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
August 11, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities

Second Quarter 2021 Revenues were $24.2 MillionIn Connection with the Transition of GLASSIA® Manufacturing, Kamada Largely Completed a Workforce Downsizing in the Second Quarter that will Result in an...
August 05, 2021 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
June 02, 2021 07:00 ET | Source: Kamada Ltd.

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

Label Expansion Differentiates KEDRAB® as the First and Only Human Rabies Immune Globulin (HRIG) Available in the U.S. to be Clinically Studied in ChildrenKEDRAB Product Label Now Includes Patients of...
May 12, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities

First Quarter 2021 Revenues were $24.9 Million, and Adjusted EBITDA was $3.7 MillionIn Connection with the Transition of GLASSIA® Manufacturing, the Product’s U.S. Biologics License Application will...
May 05, 2021 07:00 ET | Source: Kamada Ltd.

Kamada to Announce First Quarter Ended March 31, 2021 Financial Results and Host Conference Call on May 12, 2021

REHOVOT, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
April 07, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Announces Amendment to GLASSIA® License Agreement with Takeda

Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product’s US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021Kamada to...